• About
• Links
• Contact
• Sitemap

The Global Biotech Report 2006: The rise of the Biotech blockbusters

In stark contrast to the rest of the pharmaceutical industry, the world market for biotech drugs is thriving. In 2005, biotech revenues reached $60bn and visiongain predicts that this will continue.  Having grown 16.5 per cent from 2004's revenues, double-digit growth of the market will continue to the end of the decade.

- Over 250+ pages
- Over 150 tables and figures
- Global revenues & growth rates for the leading biotech drugs
- Company profiles of the leading biotech firms
- A comprehensive analysis of the global market, 2005-2011
- Revenue forecasts for the leading biotech drugs
- Revenues into therapeutic area
- Pipeline treatments
- A geographic breakdown of the market
- A Focus on biogenerics

Designed as an essential business aid, The Global Biotech Report 2006 provides a thorough evaluation of your market.

The report provides you with in-depth market analysis for all top-selling current and major potential products to arrive before the decade ends. The report extensively identifies biopharmaceuticals market potential by analysing the latest clinical trial research. The study also examines the challenges faced by potential biotech companies and opportunities newcomers to the arena. This is the industry's premier report.

Five key questions this report answer's are:
1. What are the market values of the major therapeutic areas of the global biopharmaceutical market by product from, 2005 to 2011?
2. Who are the major companies involved in the world market today and in the future, and will they be competition to you?
3. How imminent are biogenerics and what is their potential market value?
4. What strategies can be used to maximise your profits in terms of the major challenges facing biotech?
5. What's in the 2006 biopharmaceutical pipeline and what revenues can they reach by 2011?

This report is a vital addition to gaining an understanding of this highly profitable market sector and will give your company 'the edge' of your competitors. You can not afford to be without this report from visiongain.

Table of Contents

Chapter 1: Executive Summary of World Biotech Market, 2006

• 1.1 Abstract of Biotech, 2006
• 1.2 Aims, Scope and Format of Biotech, 2006

Chapter 2: Introduction to Biotechnology

• 2.1 What is Biotechnology?
• 2.2 The Uniqueness of Biopharmaceuticals: Turning Medicine Around
• 2.3 Biotechnologies Used and Their Applications to Pharma
  • 2.3.1 Bioprocessing Technology
  • 2.3.2 Monoclonal Antibodies
  • 2.3.3 Recombinant DNA Technology
  • 2.3.4 Cloning
    • 2.3.4.1 Molecular Cloning
    • 2.3.4.2 Cellular Cloning
    • 2.3.4.3 Animal Cloning
    • 2.3.4.4 Protein Engineering
• 2.4 The Future Biopharmaceutical Market
  • 2.4.1 Biopharmaceutical 2004 Market Capitalisation Worth $311bn
  • 2.4.2 Over 7000 Biotechnology Patents Granted Per Annum Since 1998
  • 2.4.3 2004 Witnessed 54 New Biopharmaceuticals Approved by the FDA
  • 2.4.4 Biopharmaceuticals Share 12.5% of 2004 Global Prescriptions

Chapter 3: Diseases Treated by Biopharmaceuticals

• 3.1 Biopharmaceuticals Are Versatile Agents
• 3.2 Orphan Diseases Are A Major Target of Biotech: 3 Out of 10 2004 Orphan Disease Drug Approvals Were Biopharmaceuticals
• 3.3 Overview of Major and Orphan Diseases Treated By Biopharmaceuticals, 2005

Chapter 4: Overview of Biopharmaceuticals Market, 2004-2005

• 4.1 Monoclonal Antibodies: Leading Class of Biopharmaceuticals in 2005 With Sales of $20bn
• 4.2 Biopharmaceuticals by Therapy Class: Blood Disorders Share Over A Quarter of the 2004 Biopharmaceuticals Market
• 4.3 2005 Biopharmaceuticals Market Worth a Staggering $59.5bn
• 4.4 The Top 20 Selling Biopharma Drugs of 2005 Accounted For 69% of Total Revenues
• 4.5 The Top 3 Biopharmaceuticals Products of 2005 Sold Over $17bn
  • 4.5.1 MAbs Lead the Market
  • 4.5.2 Procrit/Eprex - 2004's Number One Biologic - Loses Top Spot in 2005 

Chapter 5: Biotech Company Revenues and Market Share, 2005

• 5.1 Amgen: The Reign Continues With A 17% Share of 2005 Market
  • 5.1.1 Who Are Amgen?
• 5.2 The Strong Partnership Flourishes Between Roche and Genentech   
• 5.3 Collaborative Projects Grew by 30% 
• 5.4 Biotech Company Winners and Losers in 2005

Chapter 6: Biopharmaceutical Pipeline

• 6.1 Technology Driving Biopharma Pipeline
• 6.2 Biotech Targeting Chronic  Illness
• 6.3 Arthritis Biopharmaceutical Pipeline, 2006
• 6.4 MS Biopharmaceutical Pipeline, 2006
• 6.5 Late-Stage Biopharmaceutical Oncology Pipeline, 2006
• 6.6 Late Stage Biopharmaceutical Vaccine Pipeline, 2006
• 6.7 Blood Disorders Biopharmaceutical Pipeline, 2006
• 6.8 Late Stage Biopharmaceutical Endocrine Pipeline, 2006
• 6.9 Anti-Infectives Biopharmaceutical Pipeline, 2006 6.10 Enzyme Deficency Biopharmaceutical Pipeline, 2006
• 6.11 Late Stage Biopharmaceutical Opthalmic Pipeline, 2006
• 6.12 Late Stage Biopharmaceutical 'Other' Pipeline, 2006 Chapter 7: Biopharmaceutical Market Forecast by Therapeutic Area, 2005-2011
• 7.1 Blood Disorders
• 7.2 Endocrine Disorders
• 7.3 Multiple Sclerosis
• 7.4 Oncology
• 7.5 Hepatitis Treatments (inferon alpha)
• 7.6 Enzyme Deficiency Disorders
• 7.7 Vaccines
• 7.8 Arthritis
• 7.9 Others
• 7.10 Biopharmaceutical Market Set To Almost Double by 2011

Chapter 8: Summary of the 2011 Biopharmaceuticals Market

• 8.1 Enbrel Will Continue to Lead the World Biotech Market
• 8.2 Blood Disorders Will Remain Market Leaders

Chapter 9: Introduction to Biogenerics

• 9.1 The Emergence of Biogenerics
  • 9.1.1 Patent Expiry for Key Biotech Drugs
  • 9.1.2 Names are Important
• 9.2 Improved Technology Has Strengthened the Case for Biogenerics
• 9.3 Bioequivalence Will Remain Difficult to Demonstrate

Chapter 10: The Potential Biogeneric Market

• 10.1 $11bn of Biopharmaceuticals To Lose Patent Protection By 2007
• 10.2 High-Revenue Generating Biopharmaceuticals Face Patent Expiry
• 10.3 Erythropoetins are the Most Attractive Target for Biogenerics
  • 10.4.1 The Regulatory Authorities Will Require Extensive Data for EPO
• 10.4 Interferons are Going to Face High Competition from Biogenerics    

Chapter 11: Biopharmaceutical Market Challenges

• 11.1 BioTech's Delivery Challenge
  • 11.1.1 Pulmonary Delivery: An Innovative Alternative to the Needle?
  • 11.1.2 The Major Issues of the Pulmonary Pathway
  • 11.1.3 Does Protein Formulation Affect Pulmonary Delivery?
  • 11.1.4 Does Pulmonary Drug Delivery Have a Future?
  • 11.1.5 Pegylated Forms Set to Revolutionise Delivery
  • 11.1.6 Pegylation Can Extend Patent Protection - The Case of Filgrastim            
  • 11.1.7 Transdermal Technologies
  • 11.1.8 Microneedles for Transdermal Delivery of Vaccines
  • 11.1.9 Nasal Delivery Is Demonstrating Promise 11.1.10 Moving Towards Pills - Altus' Unique Technology
  • 11.1.11 New Delivery Technologies: A Pharmacy or Medical Benefit?
  • 11.1.12 Innovative Insulin Delivery Technology: The Race is On    
  • 11.1.13 Numerous Potential Blockbusting NonInjected Insulins Set to Arrive 2005-2009
• 11.2 Manufacturing Capacity Shortfall
  • 11.2.1 Why is There a Shortfall in Manufacturing Capacity for Biopharmaceuticals?
  • 11.2.2 Make Vs. Buy: The 1980s BioIndustry
  • 11.2.3 CMO Manufacturing Capacity was Adequate for the Supply of Clinical Materials Only
  • 11.2.4 Late-Stage Products have absorbed CMO Clinical Manufacturing Capacity
  • 11.2.5 How is the Manufacturing Capacity Shortfall Being Overcome?
  • 11.2.6 Does The Future for Biopharmaceutical Manufacturing Lie with Transgenics?
• 11.3 The Cost of Biopharmaceutical
  • 11.3.1 The Top Five Biopharmaceuticals Each Cost at Least $10K Per Patient Per Annum
  • 11.3.2 Monoclonal Antibodies and CSF's High Costs Reflect Production Difficulties
  • 11.3.3 Yeast-Based Systems May Bring Down the Cost of Therapeutic Proteins in the Future
• 11.4 Acquiring Capital
  • 11.4.1 Financing of Biotech Companies in 2003 Approached $17bn
• 11.5 Reliance Upon University/Company Collaborations
  • 11.5.1 The Need For Collaboration
  • 11.5.2 Biotech's Increasing Role of Commercialising       University Research
  • 11.5.3 Future Biotech Innovation Lies With Academia
  • 11.5.4 The Risky Path from Bench to Market
  • 11.5.5 Collaboration Strategies & Becoming the Partner of Choice
    • 11.5.5.1 Objectives That Support Strategic Goals
    • 11.5.5.2 Understanding the Value Brought to an Alliance
    • 11.5.5.3 Identifying and Understanding Potential Partners
    • 11.5.5.4 Due Diligence
    • 11.5.5.5 Promoting Capabilities to Potential Partners
    • 11.5.5.6 Maintaining a Relationship Through Structured Interactions
    • 11.5.5.7 Gaining Competitive Advantage
    • 11.5.5.8 Collaboration Management: Developing and Maintaining A Deal
    • 11.5.5.9 Strategic Goals to Consider
• 11.6 Regulatory Issues
  • 11.6.1 Biopharmaceuticals and the FDA
  • 11.6.2 FDA Improving Upon Biologics Approval Wait
• 11.7 Biogeneric Threat
• 11.8 Dependence upon Venture Capital Investment
• 11.9 Drivers and Restraints of Biopharmaceutical Market Growth
  • 11.9.1 Drivers
  • 11.9.2 Restraints

Chapter 12: Venture Capital Investment & Biotech

• 12.1 What is Venture Capital Investment?
• 12.2 What does VC Offer?
• 12.3 What Do Venture Capitalists Do?
• 12.4 Who Are Venture Capitalists?
  • 12.4.1 Banks as Venture Capitalists
  • 12.4.2 Business Angels (Wealthy Individuals) as Venture Capitalists
  • 12.4.3 Corporate or Direct Investors as Venture Capitalists
  • 12.4.4 Government Grants and Governments as Venture Capitalists
  • 12.4.5 Venture Capital Firms
  • 12.4.6 Other Types of Venture Capitalist
• 12.5 Why Do Biotech Companies Need VC Funding?
• 12.6 Venture Capital Investment in the US Biotech Market
  • 12.6.1 US VC Investment Now Recovering Following Stockmarket Crash in 2000
  • 12.6.2 329 US Biotech VC Investments Made in 2004, Providing Over $3.8bn
  • 12.6.3 Synta Provides 2004's Largest US Investment Sum With $80m
  • 12.6.4 MPM Capital 2004's Most Active US Biotech VC Firm
  • 12.6.5 Company Expansion Stage is the Most Favourable for VC Investment
• 12.7 Increase in VC Funding of European Biotech
• 12.8 PE European Investments in Biotech Followed Similar Trends as in the US
• 12.9 European PE Biotech Investments are a Small part of the Funding Market

Chapter 13: The Global Biopharmaceutical Market by Country and Region, 2004-2011

• 13.1 The World Biopharmaceutical Market is Dominated by the US
• 13.2 Both the Japanese and European Biotech World Market Share Set to Fall by 2011
• 13.3 The US Biotech Market Will Retain Its World Dominance
• 13.4 The European Biotech Market Will See Reduced Growth
• 13.5 European Biotech Industry Faces VC Funding Drop
• 13.6 Price Cuts in Japanese Biotech Market        
• 13.7 Asia-Pacific Region: A Dormant Giant?
• 13.8 Biotech Industries in the Asia-Pacific Region are Growing Rapidly
• 13.9 China has the Most Biotech Companies in the Asia-Pacific region
• 13.10 Other World Markets
  • 13.10.1 Russia Will See Growth in Biopharma Generics
  • 13.10.2 Israel is and Area of Biotech Industry More than Market for Biotech Drugs Chapter 14: The Human Genome Project and Its Influence on the Biotech Industry
• 14.1 Overall Project Goals
• 14.2 The Findings of the HGP:
  • 14.2.1 Gene Numbers
  • 14.2.2 Protein Coding
  • 14.2.3 Nucleotide Sequencing
  • 14.2.4 Gene Distribution
  • 14.2.5 Variations and Mutations
• 14.3 Applications and Future Developments of the HGP

Chapter 15 - Conclusions: Biotech Comes of Age

• 15.1 Big Pharma Sees Biotech as an Opportunity
• 15.2 Biotech's Major Challenges: Biogenerics and Budget Restraints

List of Tables and Figures:

Table 2.1 Definitions of Selected Biopharmaceuticals

Table 2.2 Summary of Biotechnologies

Table 3.1 Orphan Disease Biopharmaceuticals Approved By the FDA in 2004

Table 3.2 Overview to Major Diseases and Selected Orphan Diseases Treated by Biopharmaceuticals, 2005

Table 4.1 Biopharmaceuticals Revenue ($m) by Technology Class, 2005

Table 4.2 Monoclonal Antibody Products Growth Rates (%), 2005

Table 4.3 Biopharmaceuticals Revenues ($m) by Therapeutic Areas, 2005

Table 4.4 Blood Modifiers by Revenue ($m), 2005

Table 4.5 Biopharmaceutical Revenues ($m) in 2005 Top 400 by Drug Type, 2005

Table 4.6 Top 20 Selling ($m) Biopharmaceuticals, 2005

Table 5.1 Biotech Company Revenues ($m), 2004 & 2005, and 2005 Company Market Share (%)

Table 5.2 Amgen's Product Portfolio By Revenue ($m), 2005

Table 5.3 Amgen Total Revenue ($bn), 2002-2005

Table 5.4 Roche/Genentech Biopharmaceutical Portfolios By Revenue ($m), 2004 and 2005

Table 5.5 Revenues ($m) and Growth Rates (%) for Collaborative Biotech Projects, 2004-2005

Table 5.6 Revenues ($m) and Growth Rates (%) for Novo Nordisk Collaborative Biotech Projects, 2004-2005

Table 5.7 Wyeth's Product Portfolio By Revenue ($m), 2005

Table 6.1 Overview of Biotech Pipeline By Biotechnology Type, 2006

Table 6.2 Arthritis Biopharmaceutical Pipeline, 2006

Table 6.3 MS Biopharmaceutical Pipeline, 2006

Table 6.4 Late Stage Biopharmaceutical Oncology Pipelines 2006

Table 6.5 Late Stage Biopharmaceutical Vaccine Pipeline, 2006

Table 6.6 Blood Disorders Biopharmaceuticals Pipeline, 2006

Table 6.7 Late-Stage Biopharmaceutical Endocrine Pipeline, 2006  

Table 6.8 Anti-Infective Biopharmaceutical Pipeline, 2006

Table 6.9 Enzyme Deficency Disorder Biopharmaceutical Pipeline, 2006

Table 6.10 Late-Stage Biopharmaceutical Ophthalmic Pipeline, 2006

Table 6.11 Late-Stage Biopharmaceutical Others Pipeline, 2006 

Table 7.1 The Biopharmaceutical Treatment of Blood Disorder by Revenue ($m), 2004 and 2005

Table 7.2 Total World Biopharmaceutical Blood Disorder Market Forecast ($m), 2004-2011

Table 7.3 World Endocrine Biopharmaceutical by Revenue ($m), 2004 and 2005

Table 7.4 Total World Biopharmaceutical Endocrine Market Forecast ($m), 2004-2011

Table 7.5 Multiple Sclerosis Biopharmaceutical by Revenue ($m), 2004 and 2005

Table 7.6 Total World Biopharmaceutical Multiple Sclerosis Market Forecast ($m), 2004-2011

Table 7.7 Oncology Biopharmaceutical by Revenue ($m), 2004 and 2005

Table 7.8 Total World Biopharmaceutical Oncology Market Forecast ($m), 2004-2011

Table 7.9 Hepatitis Biopharmaceutical by Revenue ($m), 2004 and 2005

Table 7.10 Total World Biopharmaceutical Hepatitis Market Forecast ($m), 2004-2011

Table 7.11 Enzyme Replacement Biopharmaceutical by Revenue ($m), 2004 and 2005

Table 7.12 Total World Biopharmaceutical Enzyme Replacement Market Forecast ($m), 2004-2011

Table 7.13 Vaccine Biologics by Revenue ($m), 2004 and 2005

Table 7.14 Total World Biopharmaceutical Vaccine Market Forecast ($m), 2004-2011

Table 7.15 Arthritis Biopharmaceuticals Revenue ($m), 2004 and 2005

Table 7.16 Total World Biopharmaceutical Arthritis Market Forecast ($m), 2004-2011

Table 7.17 Other Biopharmaceuticals by Revenue ($m), 2005 and 2004

Table 7.18 Total World Biopharmaceutical Other Market Forecast ($m), 2004-2011

Table 7.19 Total Global Biopharmaceutical Market Revenue ($m) Forecast 2004-2011

Table 8.1 Top 10 Selling Biopharmaceuticals, 2011

Table 8.2 Total Global Biopharmaceutical Market Revenue ($bn) Forecast by Therapeutic Class, 2004-2011

Table 8.3 World Revenues ($bn) of Biopharmaceuticals By Therapeutic Class, 2005 & 2011Comparison

Table 8.4 Market Share (%) of Biopharmaceuticals By Therapeutic Class, 2004 & 2011 Comparison

Table 8.5 Biopharmaceuticals CAGR (%) By Therapeutic Class, 2004-2011

Table 10.1 Biopharmaceuticals facing patency expiry by 2007

Table 10.2 Revenue ($m) Forecast (2004-2011) of 6 High Profile Biopharmaceuticals Facing Patent Expiry Before 2007

Table 11.1 Mode of Administration of 2005's Top 5 Biopharmaceuticals

Table 11.2 Expected Blockbuster Noninjected Insulins From 2005

Table 11.3 Total European IPOs by Country, 2003

Table 12.1 US and European VC Investment ($m) Into Biotech Companies, 1997-2003

Table 12.2 Total US VC Investment ($bn), 1994-2004 Table 12.3US Biotech Venture Capital Investments By, 2003 vs. 2004

Table 12.4 Number of US Biotech Venture Capital Investments By Quarter, 2003 vs 2004

Table 12.5 Top 5 Largest US Biotech Investments ($m) by Company, 2004

Table 12.6 Most Active US Biotech Venture Capital Firms of 2004

Table 12.7 US VC Investments by Company Stage, 2003-2004

Table 12.8 PE European Investments ($m) in Biotech, 1997-2003

Table 13.1 Total Global Biopharmaceutical Market Revenue ($m) Forecast, 2004-2011

Table 13.2 Global Market Share (%) and Revenue ($bn) by Country/Region, 2005

Table 13.3 Global Market Share (%) and Revenue ($bn) by Country/Region, 2011

Table 13.4 US Biotech Market Revenue ($bn) Forecast, 2004-2011

Table 13.5 EU Biotech Market Revenue ($bn) Forecast, 2004-2011

Table 13.6 Asia-Pacific Biotech Market Revenue ($bn) Forecast, 2003-2010

Table 15.1Big Pharma Companies with Leading Biotech Drugs, 2005

Figure 2.1 Biopharmaceutical Market Capitalisation ($bn), 1994-2004

Figure 2.2 Total Number of Biotechnology Patents Granted: 1992-2002

Figure 2.3 Number of New Biopharmaceutical FDA Approvals: 1994-2004

Figure 2.4 Biopharmaceuticals Share of Global Prescriptions Market 1999-2004

Figure 4.1 Biopharmaceutical Market Share (%) by Class, 2005

Figure 4.2 Global Sales ($m) of Biopharmaceuticals by Technology Class, 2005

Figure 4.3 Global Sales ($m) of Biopharmaceuticals by Therapeutic Area, 2004 & 2005

Figure 4.4 Biopharmaceutical Market Share (%) by Therapeutic Class, 2005

Figure 4.5 Top 20 Selling Biopharmaceuticals Share (%) of Total Biopharmaceuticals Market

Figure 4.6 Top 20 Selling Biopharmaceuticals ($m), 2005

Figure 4.7 Global Biotech Market Share (%) for the Top 5 Selling Biopharmaceuticals, 2005

Figure 4.8 Total Revenue ($m) for Enbrel, 2002-2005

Figure 4.9 Total Revenue ($m) for Remicade, 2002-2005

Figure 4.10 Total Revenue ($m) for Rituxan/MabThera, 2002-2005

Figure 4.11 Global Procrit/Eprex Sales ($m), 2002-2005

Figure 4.12 Global Epogen Sales ($m), 2002-2005

Figure 4.13 Global Aranesp Sales ($m), 2002-2005

Figure 5.1 Company Revenues from Leading Biotech Drugs ($m), 2004 & 2005

Figure 5.2 Amgen Company Revenue ($bn), 2002-2005

Figure 5.3 Amgen Growth of Revenue (%), 2002-2004

Figure 5.4 Revenues ($m) from leading Genentech Products, 2004 and 2005

Figure 5.5 Genentech Revenues ($m), 2002-2005

Figure 5.6 Company Growth (%) in Revenue, 2004-2005

Figure 5.7 Biotech Company Market Share (%), 2005

Figure 6.1 Biopharmaceutical Pipeline by Biotechnology Type, 2005

Figure 6.2 Duration of Therapies of Biotech Pipeline Products in Late- Stage Development, 2003

Figure 6.3 Pipeline share (%) of Biopharmaceuticals Duration of Therapy, 2003

Figure 7.1 Total World Biopharmaceutical Blood Disorder Market Forecast ($m), 2004-2011

Figure 7.2 Total World Biopharmaceutical Blood Disorder Market Revenue Growth Forecast (%), 2004-2011

Figure 7.3 Total World Biopharmaceutical Endocrine Market Forecast ($bn), 2004-2011

Figure 7.4 Total World Biopharmaceutical Endocrine Market Revenue Growth Forecast (%), 2004-2011

Figure 7.5 Total World Biopharmaceutical Multiple Sclerosis Market Forecast ($bn), 2004-2011

Figure 7.6 Total World Biopharmaceutical Multiple Sclerosis Market Revenue Growth Forecast (%), 2004-2011

Figure 7.7 Total World Biopharmaceutical Oncology Market Forecast ($m), 2004-2011

Figure 7.8 Total World Biopharmaceutical Oncology  Market Revenue Growth Forecast (%), 2004-2011

Figure 7.9 Total World Biopharmaceutical Hepatitis Market Forecast ($m), 2004-2011

Figure 7.10 Total World Biopharmaceutical Hepatitis Market Revenue Growth Forecast (%), 2004-2011

Figure 7.11 Total World Biopharmaceutical Enzyme Replacement Market Forecast ($m), 2004-2011

Figure 7.12 Total World Biopharmaceutical Enzyme Replacement Market Revenue Growth Forecast  (%), 2004-2011

Figure 7.13 Total World Biopharmaceutical Vaccine Market Forecast ($m), 2004-2011

Figure 7.14 Total World Biopharmaceutical Vaccine Market Revenue Growth Forecast (%), 2004-2010

Figure 7.15 Total World Biopharmaceutical Arthritis Market Forecast ($m), 2004-2011

Figure 7.16 Total World Biopharmaceutical Arthritis Market Revenue Growth Forecast (%), 2004-2011

Figure 7.17 Total World Biopharmaceutical Other Market Forecast ($bn), 2004-2011

Figure 7.18 Total World Biopharmaceutical Other Market Revenue Growth Forecast (%), 2005-2011

Figure 7.19 Total Global Biopharmaceutical Market Revenue ($bn) Forecast 2004-2011

Figure 7.20 Total Global Biopharmaceutical Market Revenue Growth (%), 2005-2011

Figure 8.1 Top-10 Selling Biopharmaceuticals of 2011 ($m)

Figure 8.2 Market Share of the Top-10 Selling Biopharmaceuticals (%), 2011

Figure 8.3 Biopharmaceutical Therapeutic Class Market Share (%), 2005

Figure 8.4 Biopharmaceutical Therapeutic Class Market Share (%), 2011

Figure 8.5 Growth (%) of Market Share By Therapeutic Area, 2005 & 2011

Figure 8.6 Biopharmaceuticals CAGR (%) By Therapeutic Class, 2004-2011

Figure 10.1 Targets Of Biogeneric Companies By Drug Class

Figure 10.2 Total Revenue ($bn) of Five High Profile Biopharmaceuticals Facing Patent Expiry By 2007, 2004-2011

Figure 10.3 Total Revenue Growth (%) of Six High Profile Biopharmaceuticals Facing Patent Expiry By 2007, 2005-2011

Figure 10.4 Market Share for Individual Drugs in the  Interferon Market, 2005

Figure 11.1 Cost of Top Five Selling Biopharmaceuticals of 2004 ($ Per Patient Per Year)

Figure 11.2 Total Financing of Biopharmaceuticals ($bn), 2000-2003 Figure 11.3 Biotech Industry Financing By Source, 2003

Figure 11.4 Number of Pharmaceutical Alliances Formed By  Party, 1997-2001

Figure 11.5 % of Alliances Formed With Licensing, By Party During 2001

Figure 11.6 % of Alliances Formed With Development/Co-Development, By Party During 2001

Figure 11.7 % of Alliances Formed With Research, By Party During 2001

Figure 11.8 Mean FDA Approval Time For New Biopharmaceuticals, 2000-2004

Figure 12.1 US and European VC Investment ($m) Into Biotech Companies, 1997-2003

Figure 12.2 Total US VC Investment ($bn), 1994-2004

Figure 12.3 % Growth From Previous Year of Total US VC Investment, 1995-2004

Figure 12.4 Total US Biotech VC Investments ($m) By Quarter, 2003-2004

Figure 12.5 % Growth of US Biotech VC Investments By Quarter, 2003-2004

Figure 12.6 Number of Biotech VC Investments By Quarter, 2003-2004

Figure 12.7 Growth (%) of Number of US Biotech VC Investments By Quarter, 2003-2004

Figure 12.8 US VC Investments in Biotech by Company Stage, 2004

Figure 12.9 PE European Investments ($m) in Biotech, 1997-2003

Figure 12.10 % Growth of PE European Investments ($m) in Biotech, 1998-2003

Figure 13.1 Global Market Share (%) and Revenue ($bn) by Country/Region, 2005

Figure 13.2 Global Market Share (%) and Revenue ($bn) by Country/Region, 2011

Figure 13.3 US Biotech Market Revenue ($bn) Forecast, 2004-2011

Figure 13.4 US Biotech Market Revenue Growth Forecast (%), 2004-2011

Figure 13.5 EU Biotech Market Revenue ($bn) Forecast, 2004-2011

Figure 13.6 EU Biotech Market Revenue Growth Forecast (%), 2004-2011

Figure 13.7 Asia-Pacific World Biotech Market Revenue ($bn) Forecast, 2004-2011

Other users found this report page using the following search terms: biotech monoclonal antibody therapeutic protein market biotechnology biotech global world top 2006 share report 2007

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.